Chao Zhang

Chao Zhang

Auto-generated profile, based on publicly available information

Chao Zhang

State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CZChao Zhang
Chao Zhang
LWLan Wang
Lan Wang
YXYixiang Xu
Yixiang Xu
YHYunyuan Huang
Yunyuan Huang
JHJunyang Huang
Junyang Huang
JLJian Li
Jian Li

5 September 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YXYixiang Xu
Yixiang Xu
CZChao Zhang
Chao Zhang
KJKai Jiang
Kai Jiang
XYXinchun Yang
Xinchun Yang
FCFeng Chen
Feng Chen
JLJian Li
Jian Li
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reapproved for heart failure (HF) therapy in patients with and without diabetes. However, the initial glucose-lowering indication of SGLT2i has impeded their uses in cardiovascular clinical practice. A challenge of SGLT2i then becomes how to separate their anti-HF activity from glucose-lowering side-effect. To address this issue, we conducted structural repurposing of EMPA, a representative SGLT2 inhibitor, to strengthen anti-HF activity and reduce the SGLT2-inhibitory activity according to structural basis of inhibition of SGLT2. Compared to EMPA, the optimal derivative JX01, which was produced by methylation of C2–OH of the glucose ring, exhibited weaker SGLT2-inhibitory activity (IC50 > 100 nmol/L), and lower glycosuria and glucose-lowering side-effect, better NHE1-inhibitory activity and cardioprotective effect in HF mice. Furthermore, JX01 showed good safety profiles in respect of single-dose/repeat-dose toxicity and hERG activity, and good pharmacokinetic properties in both mouse and rat species. Collectively, the present study provided a paradigm of drug repurposing to discover novel anti-HF drugs, and indirectly demonstrated that SGLT2-independent molecular mechanisms play an important role in cardioprotective effects of SGLT2 inhibitors.